Sign Out
Pregnancy: There are limited amount of data from the use of dupilumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). Dupilumab should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Breast-feeding: It is unknown whether dupilumab is excreted in human milk or absorbed systemically after ingestion. A decision must be made whether to discontinue breast-feeding or to discontinue dupilumab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility: Animal studies showed no impairment of fertility (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Continue with Google